Abdelghani Omari
Director of Finance/CFO at PROTEOME SCIENCES PLC
Network origin in Abdelghani Omari first degree
Entity | Entity type | Industry | |
---|---|---|---|
19
| Public Company | Pharmaceuticals: Major | 19 |
Public Company | Medical Specialties | 8 | |
Paion Holdings UK Ltd.
Paion Holdings UK Ltd. Financial ConglomeratesFinance Part of PAION AG, Paion Holdings UK Ltd. functions as an investment holding private company. The company is based in Edinburgh, UK. The British company was founded in 1996. Abdelghani Omari has been the CEO of the company since 2012.
1
| Subsidiary | Financial Conglomerates | 1 |
Paion UK Ltd.
Paion UK Ltd. Pharmaceuticals: MajorHealth Technology Part of PAION AG, Paion UK Ltd. is a specialty pharmaceutical company that develops and commercializes innovative drugs for out-patient and hospital-based sedation and critical care services. Paion was founded in 1995 and is based in Cambridge, UK, with another site in Germany. Paion's vision is to become an acknowledged "PAIONeer" in sedation and critical care services. The British company's lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate. The private company is mainly focusing on completing the development program for procedural sedation and planning to continue the clinical development program for remimazolam in the indication general in the EU.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Paion Deutschland GmbH
Paion Deutschland GmbH BiotechnologyHealth Technology Paion Deutschland GmbH engages in the development of pharmaceutical products. The company is headquartered in Aachen, Germany.
1
| Subsidiary | Biotechnology | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Abdelghani Omari via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal | |
CeNeS Pharmaceuticals Plc
CeNeS Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology CeNeS Pharmaceuticals Plc engages in the discovery and development of drugs. The company was founded by Alan Gilbert Goodman in 1997 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer | |
DSM NV
DSM NV Chemicals: SpecialtyProcess Industries DSM BV engages in the provision of ingredients, expertise, and solutions for plant-based products. It operates through the following segments: Animal Nutrition and Health (ANH); Health, Nutrition, and Care (HNC); Food and Beverage (F and B); and Other. The ANH segment includes developing sustainable animal farming through essential products, performance solutions, and precision services serving the poultry, swine, ruminants, and aquaculture markets. The HNC segment provides health, nutrition, and care solutions for markets such as early life nutrition, dietary supplements, pharma, medical, and personal care. The F and B segment focuses on supporting healthy diets through nutritious, delicious, and sustainable solutions for several market segments including bakery, beverages and brewing, dairy, savory, plant-based alternative proteins, and pet food. The Other segment is involved in corporate activities. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands. | Chemicals: Specialty | Corporate Officer/Principal | |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Corporate Officer/Principal | |
MDXHEALTH SA | Medical Specialties | Director/Board Member | |
ALMIRALL, S.A. | Pharmaceuticals: Major | Director/Board Member | |
NOVARTIS AG | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal | |
ERGO Group AG
ERGO Group AG Insurance Brokers/ServicesFinance ERGO Group AG engages in the provision of insurance and financial services. Its business units include German, International, and Direct and digital business. The firm offers life insurance, health insurance, legal expenses insurance, property and casualty insurance, travel insurance, pension fund, and financial services. The company was founded on August 1, 1997 and is headquartered in Dusseldorf, Germany. | Insurance Brokers/Services | Director/Board Member | |
GRONTMIJ | Engineering & Construction | Director/Board Member | |
OXFORD BIOMEDICA PLC | Biotechnology | Founder Chief Executive Officer Director/Board Member | |
MOLOGEN AG | Miscellaneous Commercial Services | Chief Executive Officer | |
CURASAN AG | Pharmaceuticals: Major | Chief Executive Officer Sales & Marketing | |
BOTANIX PHARMACEUTICALS LIMITED | Pharmaceuticals: Major | Chief Executive Officer | |
Grünenthal GmbH
Grünenthal GmbH Pharmaceuticals: MajorHealth Technology Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Executive Officer | |
Booz Allen Hamilton, Inc.
Booz Allen Hamilton, Inc. Engineering & ConstructionIndustrial Services Booz Allen Hamilton, Inc. engages in the provision of management and technology consulting services. Its services include consulting, analytics, digital solutions, engineering, cyber security, and product. The company was founded by Edwin G. Booz in 1914 and is headquartered in McLean, VA. | Engineering & Construction | Corporate Officer/Principal | |
RWTH Aachen University | College/University | Doctorate Degree Doctorate Degree | |
Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree Doctorate Degree | |
Vrije Universiteit Amsterdam | College/University | Doctorate Degree | |
University of Bonn | College/University | Doctorate Degree Undergraduate Degree | |
Bayes Business School | College/University | Masters Business Admin | |
GERRESHEIMER AG | Containers/Packaging | Director/Board Member | |
Talisker Pharma Ltd. | Chief Executive Officer | ||
West Sussex Health Authority | Director/Board Member | ||
Lifegard Technologies | Director/Board Member | ||
Diabetology Ltd.
Diabetology Ltd. Miscellaneous Commercial ServicesCommercial Services Diabetology Ltd. offers biopharmaceutical research and development services. It develops Capsulin and novel Axcess oral form of insulin for diabetics that incorporates absorption enhancers with unmodified bioactive in a convenient encapsulated form. The company was founded by Roger New and Glen Travers in 2002 and is headquartered in St. Helier, Jersey. | Miscellaneous Commercial Services | Director/Board Member | |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Miscellaneous Commercial Services | Chief Executive Officer | |
Strategy&
Strategy& Miscellaneous Commercial ServicesCommercial Services Strategy& engages in the provision of global management consulting services. It serves industries including aerospace and defense; health; oil and gas; technology; automotive; entertainment and media; power and utilities; telecommunications; and transportation. The company was founded in 1914 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
SCANCELL HOLDINGS PLC | Biotechnology | Director/Board Member Director/Board Member | |
EUSA Pharma SAS
EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Biotechnology | Director/Board Member | |
Oxford Biomedica (UK) Ltd.
Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Part of Oxford Biomedica Plc, Oxford Biomedica (UK) Ltd. is a viral vector contract development and manufacturing organization (CDMO) based in Oxford, UK. Oxford Biomedica (UK has over 25 years of experience in the industry and is committed to enabling its clients to deliver life-changing therapies to patients worldwide. The British company offers innovative solutions to cell and gene therapy biotechnology and biopharma companies by working across key viral vector delivery systems including adeno-associated virus (AAV) and lentiviral delivery system. | Biotechnology | Director/Board Member | |
Trommsdorff GmbH & Co. KG
Trommsdorff GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Trommsdorff GmbH & Co. KG engages in the manufacture, development, and distribution of pharmaceuticals, as well as nutritional and dietary supplements. It also sells medical equipment and devices. The company is headquartered in Alsdorf, Germany. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Humedics GmbH
Humedics GmbH Packaged SoftwareTechnology Services Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany. | Packaged Software | Chairman | |
VITA 34 AG | Biotechnology | Director/Board Member | |
Fachhochschule Düsseldorf | College/University | Corporate Officer/Principal | |
ERGOMED | Miscellaneous Commercial Services | Director/Board Member | |
HERANTIS PHARMA OYJ | Pharmaceuticals: Major | Director/Board Member | |
ImevaX GmbH
ImevaX GmbH BiotechnologyHealth Technology ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany. | Biotechnology | Chief Executive Officer | |
Convert Pharmaceuticals SA
Convert Pharmaceuticals SA Miscellaneous Commercial ServicesCommercial Services Convert Pharmaceuticals SA provides preclinical stage drug development services. Its product hypoxia activated prodrug (HAP) is a therapeutic obstacle as it promotes the development of resistance to conventional anti-cancer treatments. The company was founded by Philippe Lambin, Nicolas Geuens, and Paul Tulcinsky on February 24, 2017 and is headquartered in Liege, Belgium. | Miscellaneous Commercial Services | Chief Executive Officer | |
Bootcamp | Founder | ||
Eusa Pharma Europe Ltd. | President | ||
W. Söhngen GmbH
W. Söhngen GmbH Medical SpecialtiesHealth Technology W. Söhngen GmbH engages in the development, production, and distribution of medical kits. It offers products for wound care as well as first aid and emergency medicine. The company is headquartered in Taunusstein, Germany. | Medical Specialties | Chief Executive Officer | |
Electrophoretics Ltd.
Electrophoretics Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 1992, Electrophoretics Ltd. is a British company that engages in research and experimental development on natural sciences. Part of Proteome Sciences Plc, the private company is based in London, UK. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Virocell Biologics Ltd.
Virocell Biologics Ltd. BiotechnologyHealth Technology Virocell Biologics Ltd. is an innovation-driven Contract Development and Manufacturing Organization (CDMO) that manufactures viral vectors and gene-modified cells to enable novel cell and gene therapies to enter clinical trials. The company is based in London, UK. The British company leverages its expertise in vector manufacture directly into the production of gene-modified cells, both adherent cells such as Mesenchymal Stromal/Stem cells and suspension cultures such as CAR T-cells. Virocell Biologics is committed to leveraging its deep experience to rapidly design and select a manufacturing strategy best suited to the client's objectives. The company was founded by Farzin Farzaneh, John W. Hadden. John W. Hadden has been the CEO since incorporation. | Biotechnology | Chairman | |
Chuangsheng Qiao Kang Pharmaceutical Co., Ltd.
Chuangsheng Qiao Kang Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chuangsheng Qiao Kang Pharmaceutical Co., Ltd. develops ocular therapeutics and treatments for rare diseases. The private company is based in Beijing, CN. and has subsidiaries in the United States. The CEO of the Chinese company is Darren Mercer. | Miscellaneous Commercial Services | Director/Board Member | |
Serono Laboratories (UK) Ltd. | Director of Finance/CFO |
Statistics
International
United Kingdom | 17 |
Germany | 17 |
United States | 6 |
Netherlands | 5 |
Belgium | 3 |
Sectoral
Health Technology | 23 |
Commercial Services | 9 |
Consumer Services | 7 |
Process Industries | 3 |
Industrial Services | 3 |
Operational
Director/Board Member | 135 |
Corporate Officer/Principal | 45 |
Chief Executive Officer | 37 |
Chairman | 28 |
Independent Dir/Board Member | 23 |
Most connected contacts
Insiders | |
---|---|
Roger McDowell | 28 |
Hans Tanner | 24 |
James Phillips | 24 |
Karin Louise Dorrepaal | 20 |
Harald F. Stock | 17 |
Irina Antonijevic | 16 |
Ursula Ney | 16 |
Alan Gilbert Goodman | 15 |
Walter Wenninger | 14 |
Mariola Söhngen | 12 |
Jürgen Beck | 9 |
John Dawson | 8 |
Michael Schlenk | 8 |
Jürgen Raths | 7 |
Martin Diggle | 7 |
- Stock Market
- Insiders
- Abdelghani Omari
- Company connections